Sorafenib Alone Versus Sorafenib Combined With HAIC for Advanced HCC
Status:
Completed
Trial end date:
2018-08-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy and safety of sorafenib combined with
hepatic arterial infusion chemotherapy (HAIC) compared with sorafenib Alone in patients with
hepatocellular carcinoma (HCC) with major portal venous tumor thrombus (PVTT).
Phase:
Phase 3
Details
Lead Sponsor:
Sun Yat-sen University
Collaborators:
First Affiliated Hospital, Sun Yat-Sen University Guangzhou No.12 People's Hospital Kaiping Central Hospital The First Affiliated Hospital of University of South China